Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer

被引：0
|
作者：
M Gijsen
P King
T Perera
P Parker
B Larijani
A Harris
A Kong
机构：
[1] University of Oxford,Cancer Research UK
[2] Johnson & Johnson Pharmaceutical Research & Development,undefined
[3] London Research Institute,undefined
来源：
Breast Cancer Research | / 12卷
关键词：
Breast Cancer; Trastuzumab; Feedback Loop; Xenograft Model; Fluorescence Resonance Energy Transfer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells
    Ding, Keshuo
    Wu, Zhengsheng
    Li, Xiaocan
    Sheng, Youjing
    Wang, Xiaonan
    Tan, Sheng
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (04): : 594 - 609
  • [22] Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient
    Yosuke Hirotsu
    Hiroshi Nakagomi
    Kenji Amemiya
    Toshio Oyama
    Masayuki Inoue
    Hitoshi Mochizuki
    Masao Omata
    Medical Oncology, 2017, 34
  • [23] Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
    Kataoka, Y.
    Mukohara, T.
    Shimada, H.
    Saijo, N.
    Hirai, M.
    Minami, H.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 255 - 262
  • [24] Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient
    Hirotsu, Yosuke
    Nakagomi, Hiroshi
    Amemiya, Kenji
    Oyama, Toshio
    Inoue, Masayuki
    Mochizuki, Hitoshi
    Omata, Masao
    MEDICAL ONCOLOGY, 2017, 34 (01)
  • [25] Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
    Johan Staaf
    Göran Jönsson
    Markus Ringnér
    Bo Baldetorp
    Åke Borg
    Breast Cancer Research, 13
  • [26] Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
    Page, David B.
    Wen, Hannah
    Brogi, Edi
    Dure, Dana
    Ross, Dara
    Spinelli, Kateri J.
    Patil, Sujata
    Norton, Larry
    Hudis, Clifford
    McArthur, Heather L.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 547 - 554
  • [27] Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
    David B. Page
    Hannah Wen
    Edi Brogi
    Dana Dure
    Dara Ross
    Kateri J. Spinelli
    Sujata Patil
    Larry Norton
    Clifford Hudis
    Heather L. McArthur
    Breast Cancer Research and Treatment, 2018, 167 : 547 - 554
  • [28] Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
    Noortje Verschoor
    Marcel Smid
    Agnes Jager
    Stefan Sleijfer
    Saskia M. Wilting
    John W. M. Martens
    Breast Cancer Research, 25
  • [29] YB-1 mediates antiestrogen resistance of breast cancer cells through ERα downregulation and HER2 upregulation
    Shibata, Tomohiro
    Watari, Kosuke
    Kawahara, Akihiko
    Sudo, Tomoya
    Murakami, Yuichi
    Izumi, Hiroto
    Akiba, Jun
    Ito, Ken-ichi
    Kuwano, Michihiko
    Ono, Mayumi
    CANCER SCIENCE, 2018, 109 : 351 - 351
  • [30] Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models
    Albrecht, Huguette
    IMMUNOTHERAPY, 2010, 2 (06) : 795 - 798
12345